The Oral Solid Dosage Contract Manufacturing Market Size is valued at 32.36 billion in 2022 and is predicted to reach 52.60 billion by the year 2031 at a 5.72% CAGR during the forecast period for 2023-2031.
Oral Solid Dosage Contract Manufacturing are the complexity of new drug compounds will all contribute to the market's expansion. Because they are affordable, easy to produce, and convenient for patients, oral solids are the dosage forms that are most commonly used in the pharmaceutical industry. Oral solids can now attain even better levels of bioavailability while requiring less frequent medication administration because of developments in drug delivery technology, including the distribution of pharmaceuticals and sustained-release formulation. The most fundamental forms of solid dosage forms are tablets and capsules.
To improve patient compliance, businesses are already utilizing cutting-edge technologies to increase the bioavailability of dose forms. Contract manufacturers for oral solid dosage forms launch or improve new products. Increased investments in infrastructure development, plant expansions, and CDMO capabilities to offer fully integrated services will boost the contract development and manufacturing industry over the coming years.
Competitive Landscape:
Some of the Oral Solid Dosage Contract Manufacturing market players are:
- Catalent Inc
- Lonza Group
- Piramal Pharma Solutions
- Aenova
- Jubilant
- Boehringer Ingelheim
- AbbVie Contract Manufacturing
- Patheon
- Recipharm
- Next Pharma AB
- Siegfried AG
- Corden Pharma
Market Segmentation:
The Oral Solid Dosage Contract Manufacturing market is categorized on the basis of product type, mechanism, and end-user. The product type segment includes tablets, capsules, powders, granules, and others (lozenges, gummies, pastilles, etc.). The mechanism segment includes immediate-release, delayed-release, and controlled-release. By end-user, the market is segmented into large-size companies, medium- & small-size companies, and others (startups & generic pharmaceutical companies).
Based On Product Type Outlook, The Tablet And Capsule Segment Is Accounted As A Significant Contributor In The Oral Solid Dosage Contract Manufacturing Market
The tablet and capsule category is expected to hold a major share of the global Oral Solid Dosage Contract Manufacturing market. This can be ascribed to the portability, simplicity in ingesting, good absorption, and medical adherence that various dose forms offer. Due to their expanded capabilities and enormous production capacities, established businesses (with over 10,000 employees) are also projected to hold over 50% of the current and future market in terms of company size.
The Controlled-Release Segment Witnessed Growth At A Rapid Rate
The market has been divided into three types based on mechanisms: controlled-release, delayed-release, and immediate-release. In 2022, the controlled-release mechanism market category had a maximum revenue share. During the projected period, the segment is also anticipated to increase at the fastest rate. Drug developers can create medications that are kinder to patients while still being effective by altering the pace and/or location at which an API is released. Controlling the release of the API allows for a reduction in the number of dosages needed per day as well as the exclusion of variations in drug plasma levels, which often lead to fewer adverse effects.
Asia Pacific Oral Solid Dosage Contract Manufacturing Market Position Maintains A Significant Revenue Share In The Region
With a significant CAGR over the projection period, Asia Pacific is anticipated to keep the quickest rate of growth in the region. Additionally, the region held the most important market share in 2021. With much lower prices, India and China are the APAC region's OSD CMO market leaders. Manufacturing of generic drugs is the second-largest source of revenue in the APAC area due to rising patent expiration rates.
CMOs are also working to achieve ISO accreditation in energy use, quality management, and environmental management. Additionally, while the quantity of warning letters has fallen in developed countries, it has risen in Asia Pacific, and transgressions of cGMP production standards have brought on most recalls. In addition, due to investments made by local businesses and increased FDA drug approval, North America is the second-most lucrative area.
Oral Solid Dosage Contract Manufacturing Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 32.36 Bn |
|
Revenue forecast in 2031 |
USD 52.60 Bn |
|
Growth rate CAGR |
CAGR of 5.72 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product Type, Mechanism, And End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Catalent Inc; Lonza Group; Piramal Pharma Solutions; Aenova; Jubilant; Boehringer Ingelheim; AbbVie Contract Manufacturing; Patheon; Recipharm; Next Pharma AB; Siegfried AG; Corden Pharma. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
